Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2022, Vol. 36 ›› Issue (4): 120-128.doi: 10.6040/j.issn.1673-3770.0.2021.388

Previous Articles    

Laryngeal cancer stem cells: potential therapeutic targets for overcoming multidrug resistance

WANG Mei1Overview,LI Zhihai2Guidance   

  1. 1.The First Clinical Medical College of WenZhou Medical University, Wenzhou 325025, Zhejiang, China;
    2.Department of Otolaryngology, Taizhou Municipal Hospital, Taizhou 317700, Zhejiang, China
  • Published:2022-07-11

Abstract: Laryngeal cancer is a common malignancy in the head and neck. Although, detection and treatment of laryngeal cancer advances have increased the possibility of early diagnosis and treatment, most patients eventually die due to drug resistance and recurrence. Therefore, drug resistance and metastasis are the major challenges in laryngeal cancer treatment. As research progresses, the existence of tumor stem cells was proven to be closely associated with tumorigenesis and treatment resistance. The early diagnosis and treatment of laryngeal cancer depend on the detection and identification of the tumor stem cell markers, which have far-reaching implications for targeted therapy of laryngeal cancer. This study reviewed the current research on laryngeal cancer stem cells at home and abroad, its origin, and possible drug resistance mechanism of laryngeal cancer stem cells. Additionally, this study reviewed the surface markers that maintain the stemness of laryngeal cancer and progress of targeted therapy for laryngeal cancer, which aims to provide new directions and targets for clinical treatment of laryngeal cancer.

Key words: Laryngeal cancer, Tumor stem cell markers, Multidrug resistance, Targeted therapy

CLC Number: 

  • R767
[1] 胡晨, 薛继尧, 龚洪立, 等. 喉鳞状细胞癌局部复发影响因素及预后分析[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(9): 773-776. doi:10.13201/j.issn.2096-7993.2020.09.002. HU Chen, XUE Jiyao, GONG Hongli, et al. Analysis of correlation factors and prognosis of local recurrence of laryngeal squamous cell carcinoma[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2020, 34(9): 773-776. doi:10.13201/j.issn.2096-7993.2020.09.002.
[2] Steuer CE, El-Deiry M, Parks JR, et al. An update on larynx cancer[J]. CA Cancer J Clin, 2017, 67(1): 31-50. doi:10.3322/caac.21386.
[3] 乐慧君, 陈思宇, 李芸, 等. 喉癌诊疗策略及进展[J]. 临床耳鼻咽喉头颈外科杂志, 2019, 33(11): 1017-1021. doi:10.13201/j.issn.1001-1781.2019.11.003. YUE Huijun, CHEN Siyu, LI Yun, et al. The progress on diagnosis and treatment of larynx cancer[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2019, 33(11): 1017-1021. doi:10.13201/j.issn.1001-1781.2019.11.003.
[4] 周春玲. 喉癌手术治疗的临床疗效及预后分析[D]. 泸州: 西南医科大学, 2020.
[5] 郭慧, 高伟, 秦多, 等. RNAi干扰Stat3基因诱导喉癌顺铂耐药细胞凋亡及对Stat3信号转导的影响[J]. 中国实验诊断学, 2017, 21(5): 873-877. GUO Hui, GAO Wei, QIN Duo, et al. RNA interference Stat3 gene induced laryngeal carcinoma cisplatin resistant cell apoptosis of Stat3 signaling pathway[J]. Chinese Journal of Laboratory Diagnosis, 2017, 21(5): 873-877.
[6] 李聪, 徐兵河. 肿瘤干细胞临床应用研究进展[J]. 中国癌症防治杂志, 2021, 13(1): 1-6. doi:10.3969/j.issn.1674-5671.2021.01.01. LI Cong, XU Binghe. Research progress in clinical application of tumor stem cells[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(1): 1-6. doi:10.3969/j.issn.1674-5671.2021.01.01.
[7] Garcia-Mayea Y, Mir C, Masson F, et al. Insights into new mechanisms and models of cancer stem cell multidrug resistance[J]. Semin Cancer Biol, 2020, 60: 166-180. doi:10.1016/j.semcancer.2019.07.022.
[8] Krause M, Dubrovska A, Linge A, et al. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments[J]. Adv Drug Deliv Rev, 2017, 109: 63-73. doi:10.1016/j.addr.2016.02.002.
[9] 杨婷, 冉宇靓. 靶向肿瘤干细胞治疗肿瘤[J]. 中国肿瘤生物治疗杂志, 2021, 28(7): 651-658. doi:10.3872/j.issn.1007-385x.2021.07.001. YANG Ting, RAN Yujing. Targeting cancer stem cells for cancer therapy[J]. Chinese Journal of Cancer Biotherapy, 2021, 28(7): 651-658. doi:10.3872/j.issn.1007-385x.2021.07.001.
[10] Battista T, Fiorillo A, Chiarini V, et al. Roles of sorcin in drug resistance in cancer: one protein, many mechanisms, for a novel potential anticancer drug target[J]. Cancers(Basel), 2020, 12(4): E887. doi:10.3390/cancers12040887.
[11] 李飞. 喉癌干细胞耐药基因的初步筛选[D].太原:山西医科大学, 2017.
[12] Cojoc M, M?倞bert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms[J]. Semin Cancer Biol, 2015, 31: 16-27. doi:10.1016/j.semcancer.2014.06.004.
[13] Roy Choudhury A, Gupta S, Chaturvedi PK, et al. Mechanobiology of cancer stem cells and their niche[J]. Cancer Microenviron, 2019, 12(1): 17-27. doi:10.1007/s12307-019-00222-4.
[14] Liu YC, Yeh CT, Lin KH. Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies[J]. Cells, 2020, 9(6): 1331. doi:10.3390/cells9061331.
[15] Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell(CSC)resistance drivers[J]. Life Sci, 2019, 234: 116781. doi:10.1016/j.lfs.2019.116781.
[16] Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic[J]. Nature, 2013, 501(7467): 355-364. doi:10.1038/nature12627.
[17] Batlle E, Clevers H. Cancer stem cells revisited[J]. Nat Med, 2017, 23(10): 1124-1134. doi:10.1038/nm.4409.
[18] Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting[J]. BMB Rep, 2017, 50(3): 117-125. doi:10.5483/bmbrep.2017.50.3.222.
[19] 杨震, 姚金光. 口腔颌面部恶性肿瘤干细胞标志物用于靶向治疗的研究进展[J]. 癌症进展, 2021, 19(7): 653-657, 728. doi:10.11877/j.issn.1672-1535.2021.19.07.02.
[20] 李梦璐, 高伟, 吴勇延, 等. 头颈部鳞状细胞癌中肿瘤干细胞生物标记物的研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2021, 35(9): 854-858. doi:10.13201/j.issn.2096-7993.2021.09.020. LI Menglu, GAO Wei, WU Yongyan, et al. Research progress of cancer stem cell biomarkers in head and neck squamous cell carcinoma[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2021, 35(9): 854-858. doi:10.13201/j.issn.2096-7993.2021.09.020.
[21] Liou GY. CD133 as a regulator of cancer metastasis through the cancer stem cells[J]. Int J Biochem Cell Biol, 2019, 106: 1-7. doi:10.1016/j.biocel.2018.10.013.
[22] Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning[J]. Blood, 1997, 90(12): 5013-5021.
[23] Liu TT, Li XF, Wang L, et al. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions[J]. Cancer Biomark, 2020, 28(3): 293-299. doi:10.3233/CBM-190196.
[24] Nagata H, Ishihara S, Kishikawa J, et al. CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis[J]. Int J Oncol, 2018, 52(3): 721-732. doi:10.3892/ijo.2018.4240.
[25] Wakizaka K, Yokoo H, Kamiyama T, et al. CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma[J]. Hepatol Res, 2020, 50(2): 258-267. doi:10.1111/hepr.13443.
[26] 廖成成, 安家兴, 谭张雪, 等. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103. LIAO Chengcheng, AN Jiaxing, TAN Zhangxue, et al. Therapeutic target and application prospects of oral squamous cell carcinoma stem cells[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(7): 1096-1103.
[27] Jang JW, Song Y, Kim SH, et al. Potential mechanisms of CD133 in cancer stem cells[J]. Life Sci, 2017, 184: 25-29. doi:10.1016/j.lfs.2017.07.008.
[28] 王晓刚. 肿瘤干细胞标志物CD133在鼻咽癌研究中的应用[J]. 海南医学, 2019, 30(14): 1874-1876. doi:10.3969/j.issn.1003-6350.2019.14.032. WANG Xiaogang. Progress in CD133 as cancer stem cell markers in nasopharyngeal carcinoma[J]. Journal of Hainan Medical University, 2019, 30(14): 1874-1876. doi:10.3969/j.issn.1003-6350.2019.14.032.
[29] 程雨涵, 龚熹, 罗玉萍. CD133(Prominin-1)的结构、功能及其相关抗体的研究进展[J]. 中国生物工程杂志, 2019, 39(5): 105-113. doi:10.13523/j.cb.20190512. CHENG Yuhan, GONG Xi, LUO Yuping. Advances in studies on the structure, function and related antibodies of CD133(prominin-1)[J]. China Biotechnology, 2019, 39(5): 105-113. doi:10.13523/j.cb.20190512.
[30] Wang J, Wu YY, Gao W, et al. Identification and characterization of CD133+CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines[J]. J Cancer, 2017, 8(3): 497-506. doi:10.7150/jca.17444.
[31] Zhou L, Wei XD, Cheng L, et al. CD133, one of the markers of cancer stem cells in Hep-2 cell line[J]. Laryngoscope, 2007, 117(3): 455-460. doi:10.1097/01.mlg.0000251586.15299.35.
[32] Chen C, Xu ZH, Wang L. The effect of morusin on stemness phenotype of laryngeal cancer stem cell[J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2020, 51(5): 650-657. doi:10.12182/20200960503.
[33] 龚小蓉. 喉癌顺铂耐药细胞株的建立及耐药机制的研究[D]. 广州: 广州医科大学, 2018.
[34] 王莹, 郭毅, 林海峰, 等. 小细胞肺癌肿瘤组织及血清CD44表达及临床预后意义[J]. 中国肺癌杂志, 2021, 24(8): 583-590. doi:10.3779/j.issn.1009-3419.2021.104.10. WANG Ying, GUO Yi, LIN Haifeng, et al. Expression of CD44 in tumor tissue and serum of small cell lung cancer and its clinical prognostic significance[J]. Chinese Journal of Lung Cancer, 2021, 24(8): 583-590. dosn.1009-3419.2021.104.10.
[35] Si DL, Yin F, Peng J, et al. High expression of CD44 predicts a poor prognosis in glioblastomas[J]. Cancer Manag Res, 2020, 12: 769-775. doi:10.2147/CMAR.S233423.
[36] Trapasso S, Garozzo A, Belfiore A, et al. Evaluation of the CD44 isoform v-6(sCD44var, v6)in the saliva of patients with laryngeal carcinoma and its prognostic role[J]. Cancer Biomark, 2016, 16(2): 275-280. doi:10.3233/CBM-150565.
[37] Kashyap T, Pramanik KK, Nath N, et al. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants(v4 and v6)in oral cancer[J]. Oral Oncol, 2018, 86: 234-243. doi:10.1016/j.oraloncology.2018.09.028.
[38] 罗大虎, 娄卫华. 临床喉鳞癌组织标本中G3BP和CD44v6的检测及意义[J]. 细胞与分子免疫学杂志, 2017, 33(7): 977-982. doi:10.13423/j.cnki.cjcmi.008201. LUO Dahu, LOU Weihua. Dectection of G3BP and CD44v6 in the tissues of laryngeal squamous cell carcinoma and their clinical significance[J]. Chinese Journal of Cellular and Molecular Immunology, 2017, 33(7): 977-982. doi:10.13423/j.cnki.cjcmi.008201.
[39] 谢亚学, 尚小领, 范婕. RhoA、Ezrin和CD44在喉鳞状细胞癌组织中的表达及临床意义[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(3): 191-194. doi:10.13201/j.issn.1001-1781.2017.03.006. XIE Yaxue, SHANG Xiaoling, FAN Jie. The expression and clinical significance of RhoA, Ezrin and CD44 in laryngeal squamous cell carcinoma[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2017, 31(3): 191-194. doi:10.13201/j.issn.1001-1781.2017.03.006.
[40] 马爽, 乔娜, 张静, 等. 肿瘤干细胞标志物ALDH1在恶性肿瘤中表达特点与预后关系的研究进展[J]. 医学综述, 2020, 26(5): 920-923, 929. doi:10.3969/j.issn.1006-2084.2020.05.017. MA Shuang, QIAO Na, ZHANG Jing, et al. Research progress of ALDH1-marker of cancer stem cells on malignant tumor and its relationship with prognosis[J]. Medical Recapitulate, 2020, 26(5): 920-923, 929. doi:10.3969/j.issn.1006-2084.2020.05.017.
[41] Kulsum S, Sudheendra HV, Pandian R, et al. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition[J]. Mol Carcinog, 2017, 56(2): 694-711. doi:10.1002/mc.22526.
[42] Zhao Y, Jin X, Li N, et al. Expressions and significance of ALDH1, HIF-1α and VEGF in laryngeal squamous cell carcinoma[J]. J Sichuan Univ Med Sci Ed, 2017, 48(3): 399-404.
[43] 李冬雷, 张旭宇, 肖跃华, 等. 喉癌组织中Oct4、Nanog、β-catenin的表达情况及临床意义[J]. 癌症进展, 2020, 18(2): 148-151, 175. doi:10.11877/j.issn.1672-1535.2020.18.02.10. LI Donglei, ZHANG Xuyu, XIAO Yuehua, et al. The expression and clinical significance of Oct4, Nanog and β-catenin in laryngeal carcinoma[J]. Oncology Progress, 2020, 18(2): 148-151, 175. doi:10.11877/j.issn.1672-1535.2020.18.02.10.
[44] Kumbar VM, Muddapur UM, Bhat KG, et al. Cancer stem cell traits in tumor spheres derived from primary laryngeal carcinoma cell lines[J]. Contemp Clin Dent, 2021, 12(3): 247-254. doi:10.4103/ccd.ccd_252_20.
[45] Novak D, Hüser L, Elton JJ, et al. SOX2 in development and cancer biology[J]. Semin Cancer Biol, 2020, 67(Pt 1): 74-82. doi:10.1016/j.semcancer.2019.08.007.
[46] Chaudhary S, Islam Z, Mishra V, et al. Sox2: a regulatory factor in tumorigenesis and metastasis[J]. Curr Protein Pept Sci, 2019, 20(6): 495-504. doi:10.2174/1389203720666190325102255.
[47] Mohammad IS, He W, Yin LF. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR[J]. Biomed Pharmacother, 2018, 100: 335-348. doi:10.1016/j.biopha.2018.02.038.
[48] 苏甜甜, 张佳, 孙臻峰. 多药耐药基因蛋白P-gp和ABCG2在喉癌等头颈肿瘤中的作用及相关信号通路[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 103-106. SU Tiantian, ZHANG Jia, SUN Zhenfeng. Roles of multidrug resistance proteins P-gp and ABCG2 in laryngocatcinoma and their related signal pathways[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2016, 30(3): 103-106.
[49] 于锋, 龚小蓉, 周毅波. 喉癌顺铂耐药细胞株的建立及干性生物学特性分析[J]. 中国耳鼻咽喉颅底外科杂志, 2018, 24(1): 39-44. doi:10.11798/j.issn.1007-1520.201801009. YU Feng, GONG Xiaorong, ZHOU Yibo. Establishment of a cisplatin-resistant human laryngeal carcinoma cell line and its stem cell biological characteristics[J]. Chinese Journal of Otorhinolaryngology-Skull Base Surgery, 2018, 24(1): 39-44. doi:10.11798/j.issn.1007-1520.201801009.
[50] 何佳怡, 卫旭东, 何健, 等. 葫芦素E对人喉癌干细胞生理活动的影响及分子机制探究[J]. 中国现代药物应用, 2019, 13(9): 232-234. doi:10.14164/j.cnki.cn11-5581/r.2019.09.135. HE Jiayi, WEI Xudong, HE Jian, et al. Investigation of effects of cucurbitacin E on physiological activities of human laryngeal cancer stem cells and its molecular mechanisms[J]. Chinese Journal of Modern Drug Application, 2019, 13(9): 232-234. doi:10.14164/j.cnki.cn11-5581/r.2019.09.135.
[51] Qi XM, Yu D, Jia B, et al. Targeting CD133(+)laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles[J]. Tumour Biol, 2016, 37(2): 2209-2217. doi:10.1007/s13277-015-4007-9.
[52] 陈靖昀, 于书剑, 肖冬. 刺五加多糖对肿瘤干细胞的作用研究[J]. 中国实验诊断学, 2019, 23(7): 1233-1238. doi:10.3969/j.issn.1007-4287.2019.07.044. CHEN Jingyun, YU Shujian, XIAO Dong. The effection of Acanthopanax senticosus polysaccharide on cancer stem cells[J]. Chinese Journal of Laboratory Diagnosis, 2019, 23(7): 1233-1238. doi:10.3969/j.issn.1007-4287.2019.07.044.
[53] 王彬蓉, 应畅, 方慧玲, 等. 人喉癌干细胞的培养鉴定及其增殖的抑制研究[J]. 中国细胞生物学学报, 2019, 41(6): 1100-1106. doi:10.11844/cjcb.2019.06.0012. WANG Binrong, YING Chang, FANG Huiling, et al. The indentification and suppression effection of proliferation on human laryngeal cancer stem cell[J]. Chinese Journal of Cell Biology, 2019, 41(6): 1100-1106. doi:10.11844/cjcb.2019.06.0012.
[54] 石浩伟, 郝少龙, 纪宇, 等. 低氧微环境对胰腺癌影响的研究进展[J]. 中华普外科手术学杂志(电子版), 2021, 15(3): 351-354. SHI Haowei, HAO Shaolong, JI Yu, et al. Research progress on the effect of hypoxic microenvironment on pancreatic cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(3): 351-354.
[55] Liu ML, Zhong JX, Zeng Z, et al. Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein[J]. Theranostics, 2019, 9(16): 4795-4810. doi:10.7150/thno.30988.
[56] 孙庆佳. 周期性低氧诱导喉癌细胞化疗抵抗的作用机制[D]. 长春: 吉林大学, 2012.
[57] 高伟, 邬信芳, 李钦. 缺氧诱导因子-1α在喉癌中的研究进展[J]. 中国眼耳鼻喉科杂志, 2021, 21(3): 230-233. doi:10.14166/j.issn.1671-2420.2021.03.022. GAO Wei, WU Xinfang, LI Qin. Research progress on hypoxia inducible factor-1α in laryngeal cancer[J]. Chinese Journal of Ophthalmology and Otorhinolaryngology, 2021, 21(3): 230-233. doi:10.14166/j.issn.1671-2420.2021.03.022.
[58] 钟江涛. 靶向抑制喉癌干细胞GLUT-1提高喉癌放射敏感性机制的体内外研究[D]. 杭州: 浙江大学, 2018.
[59] Song K, Farzaneh M. Signaling pathways governing breast cancer stem cells behavior[J]. Stem Cell Res Ther, 2021, 12(1): 245. doi:10.1186/s13287-021-02321-w.
[60] 勾蓉. 肿瘤干细胞信号通路(PI3K/AKT)研究与进展[J]. 哈尔滨医药, 2021, 41(1): 139-141. GOU Rong. Research and development in the signal pathway of cancer stem cells(PI3K/AKT)[J]. Harbin Medical Journal, 2021, 41(1): 139-141.
[61] Liu R, Chen YW, Liu GZ, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers[J]. Cell Death Dis, 2020, 11(9): 797. doi:10.1038/s41419-020-02998-6.
[62] Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, et al. WNT signaling in tumors: the way to evade drugs and immunity[J]. Front Immunol, 2019, 10: 2854. doi:10.3389/fimmu.2019.02854.
[63] Ghandadi M, Valadan R, Mohammadi H, et al. Wnt-β-catenin signaling pathway, the Achilles's; heels of cancer multidrug resistance[J]. Curr Pharm Des, 2019, 25(39): 4192-4207. doi:10.2174/1381612825666191112142943.
[64] 唐晓敏. 靶向下调YAP通过调控EMT进程及Wnt/β-catenin通路抑制喉癌恶性进展[D]. 合肥: 安徽医科大学, 2019.
[65] 宋毅昌. Notch信号通路在增强骨肉瘤化学治疗药物疗效中的机制[J]. 中南大学学报(医学版), 2020, 45(10): 1234-1240. doi:10.11817/j.issn.1672-7347.2020.190147. SONG Yichang. Mechanism of the Notch signaling pathway in enhancing the efficacy of chemotherapy drugs in osteosarcoma[J]. Journal of Central South University(Medical Science), 2020, 45(10): 1234-1240. doi:10.11817/j.issn.1672-7347.2020.190147.
[66] Majidinia M, Alizadeh E, Yousefi B, et al. Downregulation of Notch signaling pathway as an effective chemosensitizer for cancer treatment[J]. Drug Res(Stuttg), 2016, 66(11): 571-579. doi:10.1055/s-0042-111821.
[67] Ashry R, Elhussiny M, Abdellatif H, et al. Genetic interpretation of the impacts of honokiol and EGCG on apoptotic and self-renewal pathways in HEp-2 human laryngeal CD44high cancer stem cells[J]. Nutr Cancer, 2022, 74(6):2152-2173. doi:10.1080/01635581.2021.1981404.
[68] 管玲男, 刘哲, 王欢, 等. JAK/STAT3信号通路及其抑制剂在肿瘤治疗领域的研究进展[J]. 中国药学杂志, 2018, 53(23): 1973-1977. GUAN Lingnan, LIU Zhe, WANG Huan, et al. JAK/STAT3 signaling pathway and its inhibitors in tumor therapy[J]. Chinese Pharmaceutical Journal, 2018, 53(23): 1973-1977.
[69] 张炜, 魏珍星, 张杨, 等. 高迁移率蛋白-1对喉癌Hep-2细胞顺铂耐药的作用机制[J]. 中华实用诊断与治疗杂志, 2021, 35(2): 116-121. doi:10.13507/j.issn.1674-3474.2021.02.003. ZHANG Wei, WEI Zhenxing, ZHANG Yang, et al. Mechanism of high mobility protein-1 on resistance of laryngeal carcinoma Hep-2 cells to cisplatin[J]. Journal of Chinese Practical Diagnosis and Therapy, 2021, 35(2): 116-121. doi:10.13507/j.issn.1674-3474.2021.02.003.
[70] 郭洁, 张晓双. 太白山藤梨根提取物对喉癌干细胞侵袭和转移的影响[J]. 临床合理用药杂志, 2020, 13(12): 89-92. doi:10.15887/j.cnki.13-1389/r.2020.12.042.
[71] Kyurkchiyan SG, Popov TM, Mitev VI, et al. The role of miRNAs and lncRNAs in laryngeal squamous cell carcinoma-a mini-review[J]. Folia Med(Plovdiv), 2020, 62(2): 244-252. doi:10.3897/folmed.62.e49842.
[72] 何丹, 王苹, 李亚纯, 等. MiRNA210通过NUPR1基因靶向调控喉癌多药耐药性的研究[J]. 中国实验诊断学, 2019, 23(3): 511-515. doi:10.3969/j.issn.1007-4287.2019.03.053. HE Dan, WANG Ping, LI Yachun, et al. The study of miRNA210 regulation in Multidrug resistance of laryngeal cancer through targeted NUPR1 gene[J]. Chinese Journal of Laboratory Diagnosis, 2019, 23(3): 511-515. doi:10.3969/j.issn.1007-4287.2019.03.053.
[73] Lin XJ, Liu H, Li P, et al. miR-936 suppresses cell proliferation, invasion, and drug resistance of laryngeal squamous cell carcinoma and targets GPR78[J]. Front Oncol, 2020, 4(10): 60. doi:10.3389/fonc.2020.00060.
[74] Chang YC, Jan CI, Peng CY, et al. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas[J]. Oncotarget, 2015, 6(27): 24002-24016. doi:10.18632/oncotarget.4365.
[75] 郭海啸, 栾婷, 王海峰, 等. 肿瘤干细胞在化疗耐药机制中的研究进展[J]. 实用医学杂志, 2019, 35(1): 163-166. doi:10.3969/j.issn.1006-5725.2019.01.037.
[76] Wei XD, He J, Wang JY, et al. MPEG-CS/bmi-1RNAi nanoparticles synthesis and its targeted inhibition effect on CD133+ laryngeal stem cells[J]. J Nanosci Nanotechnol, 2018, 18(3): 1577-1584. doi:10.1166/jnn.2018.14303.
[77] Zhang YX, Sun XC. Role of focal adhesion kinase in head and neck squamous cell carcinoma and its therapeutic prospect[J]. Onco Targets Ther, 2020, 13: 10207-10220. doi:10.2147/OTT.S270342.
[1] WANG Xiaoting, CHEN Zhengnong, YI Hongliang. Transcriptomic analysis of glutamine deprivation on laryngeal carcinoma cells [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 26-31.
[2] LI Yanjie, JIA Jian, YANG Ping, WAN Baoluo. Study on the value of tumor abnormal protein in clinical diagnosis of laryngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 70-74.
[3] WEI Ya'nanOverview,CHEN XiGuidance. Progress in chemotherapy and targeted drug therapy for locally advanced head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 118-124.
[4] LI WenjingOverview,LIU MingGuidance. Research progress on the relationship between the C2H2 zinc finger protein family and laryngeal cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(1): 125-130.
[5] To investigate the swallowing function recovery on 23 cases of supraglottic laryngeal carcinoma postoperation. MethodsFrom 2016 to 2019, a retrospective swallowing function analysis was performed on 23 cases of supraglottic laryngeal carcinoma. All of the patients underwent horizontal hemilaryngectomy and reconstruction with tongue flap. The M.D. Anderson Dysphasia Inventory(MDADI)was used to evaluate the swallowing function from emotional dimension, social function dimension, and physiological dimension before and after operation. Results2 patients died during follow-up period.1 case lost follow-up. 20 patients recovered to normal diet. The overall swallowing median score was 90.00[80.00,100.00], and the postoperative score median was 80.00[80.00,80.00](P=0.359).The median score of emotion dimension was 91.67[77.50,93.33], 80.00[80.00,83.33](P=0.065)after operation. The median score of social function was 90.00[80.00,96.00]before surgery, and 84.00[80.00,92.00](P=0.587)after surgery. Physiological function median score was 83.75[76.25,89.38], 80.00[75.00,84.38](P=0.018)after surgery. ConclusionTongue flap can improve the swallowing function and the quality of patient life after the horizontal hemilaryngectomy.. The swallowing function recovery study on tongue flap after horizontal hemilaryngectomy [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(5): 127-131.
[6] QING Xiaoyan, XU YiquanOverview, LI ChaoGuidance. Advances in molecular mechanisms of anaplastic thyroid cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 26-31.
[7] Haijun LU,Ji LIU,Xiao DING. Progress in the comprehensive treatment for nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 26-30.
[8] WU Jing, LIU Yehai. Targeted therapy for head and neck squamous cell carcinoma [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 97-102.
[9] XU Yuanteng, CHEN Ruiqing, LIN Gongbiao, FANG Xiuling, YU Shujuan, LIANG Xiaohua, ZHANG Rong. Effect of silencing PDCD4 gene on proliferation of Hep-2 cells and the expression of β-catenin by RNA interference technique. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 110-114.
[10] LI Xiaoming, SONG Qi, LI Hongxia, TAO Zhenfeng, SHEN Yupeng, XIAO Shufen. Reconstruction of hypopharyngeal defects after ablation of advanced head and neck squamous carcinoma involving hypophaynx with pectoralis major myocutaneous flap. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 4-9.
[11] SU Tiantian, ZHANG Jia, SUN Zhenfeng. Roles of multidrug resistance proteins P-gp and ABCG2 in laryngocatcinoma and their related signal pathways. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 103-106.
[12] LIN Dan, DONG Wei-da, LU Mei-ping, XING Guang-qian, DONG Jia-di, ZHANG Wei-qiang. The association between rs2910164 G>C polymorphism in pre-microRNA-146a and laryngeal cancer in Jiangsu Han population [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(2): 46-50.
[14] SHI Da-zhi1, LUO Zhi-qiang1, ZHOU Jun2. Expression and significance of serum soluble tumor necrosis factor  receptor  Ⅰ and  Ⅱ in patients with laryngeal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2010, 24(5): 10-12.
[15] LI Qing-feng, ZHANG Zhong-xiang, ZHANG Guo-kui, LI Qiang. Supraglottic horizontal laryngectomy via supra-anterior commissure approach [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2010, 24(4): 13-15.
Full text



No Suggested Reading articles found!